DOCSLIB.ORG

Wilson Disease: Case Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wilson Disease: Case Presentation Hepatolenticular Degeneration AshutoshAshutosh Barve,Barve, M.D.,M.D., Ph.D.Ph.D. Gastroenterology/HepatologyGastroenterology/Hepatology FellowFellow UniversityUniversity ofof LouisvilleLouisville Case Presentation 1717 yearyear oldold caucasiancaucasian womanwoman withwith nono previousprevious medicalmedical historyhistory PresentsPresents withwith aa 22--33 dayday historyhistory ofof rightright andand leftleft upperupper quadrantquadrant pain,pain, abdominalabdominal distensiondistension andand bilateralbilateral LELE edemaedema SheShe alsoalso c/oc/o fatiguefatigue forfor aboutabout 66 weeksweeks alongalong withwith subjectivesubjective feversfevers andand occasionaloccasional headacheheadache Case Presentation PHYSICALPHYSICAL EXAM:EXAM: ¾ RightRight upperupper quadrantquadrant tendernesstenderness ¾ SlightSlight abdominalabdominal distensiondistension ¾ SoftSoft abdomenabdomen withwith nono hepatospleenomeg.hepatospleenomeg. ¾ 2+2+ bilateralbilateral lowerlower extremityextremity edemaedema ¾ NormalNormal cardiocardio--respiratoryrespiratory examexam ¾ NormalNormal neurologicalneurological examexam Case Presentation INITIALINITIAL LABORATORYLABORATORY DATA:DATA: ¾ Na=134,Na=134, K=K= 3.4,3.4, Cl=107,Cl=107, CO2=23,CO2=23, ¾ BUN=11,BUN=11, Cr=1.0Cr=1.0 ¾ Hgb=11.4,Hgb=11.4, Hct=33.4,Hct=33.4, Ptt=144,Ptt=144, WBC=7.6WBC=7.6 ¾ AST=148,AST=148, ALT=83ALT=83,, AlkP=73,AlkP=73, TBil=1.6TBil=1.6 ¾ Alb=2.5Alb=2.5,, TProt=6.1TProt=6.1 ¾ PT=20.7PT=20.7,, PTT=45.5PTT=45.5 Case Presentation RADIOLOGY:RADIOLOGY: ¾ ChestChest XX--rayray –– normalnormal ¾ AbdominalAbdominal USUS –– moderatemoderate ascites,ascites, mildmild diffusediffuse thicknessthickness ofof thethe gallgall bladderbladder wallwall consistentconsistent withwith hepatitis,hepatitis, otherwiseotherwise normalnormal SheShe waswas admittedadmitted withwith aa provisionalprovisional diagnosisdiagnosis ofof hepatitishepatitis vs.vs. mononucleosismononucleosis withwith hepatichepatic involvementinvolvement Case Presentation FURTHERFURTHER WORKWORK UP:UP: ¾ Ferritin=231Ferritin=231 ¾ ANA=neg,ANA=neg, AMA=neg,AMA=neg, ASMA=negASMA=neg ¾ HepatitisHepatitis profile=negprofile=neg ¾ MonospotMonospot test=negtest=neg ¾ Ceruloplasmin=13Ceruloplasmin=13 mg/dLmg/dL (normal(normal 2020-- 45)45) Case Presentation FURTHERFURTHER WORKWORK UP:UP: ¾ SlitSlit lamplamp examexam byby OphthalmologyOphthalmology revealedrevealed KayserKayser--FleischerFleischer ringsrings ¾ 2424 hrhr urineurine coppercopper == 32003200 mcg/Lmcg/L (normal(normal 55--3030 mcg/L)mcg/L) ¾ LiverLiver BiopsyBiopsy waswas donedone andand samplessamples sentsent forfor lightlight andand electronelectron microscopymicroscopy Case Presentation LiverLiver Biopsy:Biopsy: ¾ LightLight Microscopy:Microscopy: ““ChronicChronic activeactive hepatitishepatitis withwith earlyearly cirrhosis.cirrhosis. AA smallsmall amountamount ofof stainablestainable coppercopper isis demonstrateddemonstrated……..”” Case Presentation LiverLiver biopsy:biopsy: ¾ ElectronElectron Microscopy:Microscopy: “…“….In.In somesome ofof thethe nucleinuclei areare foundfound accumulationsaccumulations ofof glycogenglycogen particlesparticles…….Many.Many mitochondriamitochondria areare ofof giantgiant sizesize andand bizarrebizarre shapesshapes……InIn additionaddition thethe membranesmembranes ofof thethe cristaecristae areare widenedwidened formingforming smallsmall andand largelarge electronelectron--lucentlucent roundround swellingsswellings borderedbordered byby aa singlesingle membranemembrane.. AlsoAlso notednoted inin thethe mitochondriamitochondria areare variousvarious electronelectron--densedense granulesgranules……....”” Impression:Impression: ElectronElectron microscopymicroscopy ofof thisthis adequateadequate liverliver biopsybiopsy isis consistentconsistent withwith WilsonWilson’’ss diseasedisease Samuel Alexander Kinnier Wilson Neurologist and Pathologist Born in New Jersey, USA Lived and worked in England Professor of Neurology at King’s College Hospital Great clinician and teacher, proficient linguist, keen gardener and avid golfer PROGRESSIVEPROGRESSIVE LENTICULARLENTICULAR DEGENERATION:DEGENERATION: AA FAMILIALFAMILIAL NERVOUSNERVOUS DISEASEDISEASE ASSOCIATEDASSOCIATED WITHWITH CIRRHOSISCIRRHOSIS OFOF THETHE LIVER.LIVER. WILSONWILSON SAK,SAK, Brain.Brain.1912;1912; 34:34: 295295-- 507.507. Wilson Disease AutosomalAutosomal recessiverecessive PrevalencePrevalence ofof approximatelyapproximately 11 casecase inin 30,00030,000 livelive birthsbirths inin mostmost populationspopulations DefectDefect inin hepatichepatic coppercopper transporttransport leadingleading toto accumulationaccumulation ofof coppercopper inin thethe liverliver ExcessExcess coppercopper actsacts asas aa propro--oxidantoxidant andand promotespromotes thethe generationgeneration ofof freefree radicalsradicals leadingleading toto hepatocytehepatocyte injury.injury. Synonyms of Wilson Disease HepatolenticularHepatolenticular DegenerationDegeneration ProgressiveProgressive LenticularLenticular DegenerationDegeneration KinnierKinnier WilsonWilson’’ss DiseaseDisease WestphalWestphal--StrumpellStrumpell’’ss pseudosclerosispseudosclerosis Historical Perspective 18601860 –– FrerichsFrerichs describesdescribes aa casecase similarsimilar toto thosethose describeddescribed byby WilsonWilson 19121912 –– WilsonWilson publishespublishes hishis casecase seriesseries 19121912 –– EyeEye findingsfindings associatedassociated withwith WDWD describeddescribed byby KayserKayser andand FleischerFleischer 19291929 –– VogtVogt andand HaurowitzHaurowitz && GlazebrookGlazebrook reportreport excessexcess coppercopper inin thethe brainbrain andand liverliver ofof WDWD patientspatients Historical Perspective 19361936 –– PolicardPolicard etet alal demonstratedemonstrate excessexcess coppercopper inin thethe cornealcorneal KFKF ringring 19561956 –– BennettsBennetts andand ChapmanChapman establishestablish relationshiprelationship betweenbetween abnormalabnormal coppercopper metabolismmetabolism andand WDWD 19521952 –– SternliebSternlieb andand GitlinGitlin describedescribe anan almostalmost universaluniversal lowlow ceruloplasminceruloplasmin inin WDWD 19931993 –– TheThe genegene thatthat isis abnormalabnormal inin WDWD isis identifiedidentified (Nature(Nature Genetics)Genetics) Copper Physiology (60% absorbed) Feldman: Sleisenger & Fordtran Gastrointestinal and Liver Diseases, 7th Ed Diseases of Copper Transport Menkes'Menkes' Disease:Disease: ¾ XX--linkedlinked geneticgenetic disorderdisorder ¾ DefectDefect inin thethe transporttransport ofof coppercopper fromfrom thethe intestine,intestine, leadingleading toto coppercopper deficiencydeficiency ¾ ResultsResults inin deathdeath fromfrom severesevere progressiveprogressive neurodegenerationneurodegeneration WilsonWilson DiseaseDisease ¾ DecreasedDecreased transporttransport ofof coppercopper fromfrom thethe liverliver intointo bile,bile, leadingleading toto coppercopper excessexcess Diseases of Copper Transport MenkeMenke’’ss Disease:Disease: ¾ XX--linkedlinked disorderdisorder ¾ GeneGene productproduct isis ATP7AATP7A WilsonWilson’’ss DiseaseDisease ¾ GeneticGenetic defectdefect localizedlocalized toto ChromosomeChromosome 1313 ¾ GeneGene productproduct isis ATP7BATP7B –– highhigh degreedegree ofof homologyhomology withwith ATP7AATP7A ATP7B Gene Product P-Type ATPase 1443 amino acids, 6 copper-binding motifs, 1 ATP binding region Feldman: Sleisenger & Fordtran Gastrointestinal and Liver Diseases, 7th Ed Hepatocyte Copper Transport ATP7B Copper Apoceruloplasmin ceruloplasmin Hepatocyte Copper Transport Genetic Basis of Wilson’s Disease MoreMore thanthan 100100 mutationsmutations inin thethe genegene havehave alreadyalready beenbeen identifiedidentified inin patientspatients withwith Wilson'sWilson's diseasedisease MostMost patientspatients areare compoundcompound heterozygotesheterozygotes Histidine1069GlutamineHistidine1069Glutamine mutationmutation isis oneone ofof thethe mostmost frequentfrequent mutationmutation withwith anan allelicallelic frequencyfrequency ofof 1010 toto 4040 percentpercent Pathology EarliestEarliest lesionlesion inin WilsonWilson DiseaseDisease isis fattyfatty infiltrationinfiltration withinwithin hepatocytes,hepatocytes, glycogenglycogen inclusionsinclusions withinwithin nuclei,nuclei, andand portalportal fibrosisfibrosis Pathology AsAs thethe diseasedisease progressesprogresses thethe histologichistologic lesionlesion resemblesresembles thatthat ofof AutoimmuneAutoimmune ChronicChronic HepatitisHepatitis ThereThere isis portalportal inflammationinflammation andand fibrosis,fibrosis, piecemealpiecemeal necrosis,necrosis, withwith markedmarked swellingswelling andand necrosisnecrosis ofof periportalperiportal hepatocyteshepatocytes Pathology UltimatelyUltimately thethe inflammationinflammation andand fibrosisfibrosis leadsleads toto CirrhosisCirrhosis Clinical Presentation MajorityMajority ofof clinicalclinical casescases presentpresent betweenbetween thethe agesages ofof 55 andand 3535 YoungestYoungest casecase inin thethe literatureliterature waswas aa 33 yearyear oldold patientpatient OldestOldest patientspatients describeddescribed werewere 22 siblingssiblings inin theirtheir seventiesseventies VariabilityVariability inin ageage probablyprobably reflectsreflects differencesdifferences inin mutationsmutations andand penetrancepenetrance asas wellwell asas extragenicextragenic factors.factors. Clinical Presentation ThereThere areare twotwo principleprinciple presentationspresentations
Load more

Recommended publications
  • Syllabus METAL ION EXCESS TOXICITY
    Syllabus Metalionexcesstoxicity-Feexcesstoxicity-Africansiderosis,hemosiderosis, hemochromatosis(bronzediabetes)anddetoxification.Cuexcesstoxicity:Wilson’sdisease andtreatment. Heavymetaliontoxicity:Hg,Pb,Cd,Astoxiceffects–mechanismoftoxiceffects.Heavy metaltoxicitytreatment-chelationtherapy:chelatingagentsforHg,Pb,Cd,Astoxicity. Metalcomplexesasdrugs:cis-plainasanticanceragent:mechanismofactionandside effects;goldcomplexesasantiarthriticdrugs-chrysotherapy.Metalcomplexesindiagnosis- Gdcomplexesinmagneticresonanceimaging(MRI). METALIONEXCESSTOXICITY Ironexcesstoxicity ü ItisduetoaccidentalintakeofFeSO4tabletscausingerosionofthegastrointestinal tract. ü Hemochomatosisisageneticdisorder,depositionofironoccursinvitalorganslike liver,spleen,pancreas,skinetc.Itleadstobronzepigmentationontheskiniscalled bronzediabetes. ü Siderosis(depositionofFeOdustinthelungs)isassociatedwithexcessofiron. ü AfricansiderosisisanironoverloaddisorderfirstobservedamongpeopleofSouthern AfricaandCentralAfrica.Dietaryironoverloadistheconsumptionoflargeamount ofhome-brewedbeerwithhighamountofironcontentinit. Detoxification : Siderophore desferrioxamine is a chelating antidote used for Fe removal Coppertoxicity Copper is a principal component of several metalloproteins and some naturally occurring pigments.Ahealthyadultpossessescopperbetween200to300mgandthehighestamountis concentratedin the locus of brain. Wilson’sdiseaseand Menkes’ kinky hair syndromeare associatedwithageneticdisorderinthemetabolismofcopper. Wilson’sdisease ü In Wilson'sdisease,the copper-content
    [Show full text]
  • Chelation Therapy
    Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder.
    [Show full text]
  • Nr 1. Each Patient Suffering from Acute Coronary Syndrome Must Be Treated With
    SED - 3 - VERSION I February 2009 Nr 1. Each patient suffering from acute coronary syndrome must be treated with: A. Acetylsalicylic acid (ASA). B. ASA or clopidogrel. C. ASA and clopidogrel. D. depending on the type of myocardial infarction – ASA and clopidogrel or ASA only. E. depending on the mode of treatment (invasive vs noninvasive) – ASA and clopidogrel or ASA only. Nr 2. A patient in the class IV of Killip-Kimball classification has: A. pulmonary oedema. B. cardiogenic shock. C. blood retention (haemostasis) below the level of inferior angles of scapulae. D. no signs of heart insufficiency. E. chronic heart insufficiency, previously at least in NYHA class III. Nr 3. Schőnlein-Henoch purpura is a vasculitis that: A. is characterized by nephritic syndrome with cANCA antibodies. B. may present as rapidly progressive glomerulonephritis. C. is often accompanied by granulomas in the lungs. D. is typically treated by a surgical excision of granuloma. E. is typically treated by nephrectomy of the kidney with granulomas. Nr 4. Which of the below given drugs can cause hyperkalemia? 1) angiotensin converting enzyme inhibitors. 2) loop diuretics. 3) aldosterone antagonist. 4) thiazide. 5) indapamide. The correct answer is: A. 1,3. B. 1,2,3. C. 1,3,4. D. 1,3,5. E. all of the above. Nr 5. Which of the below is an absolute contraindication to thrombolytic therapy in acute myocardial infarction: A. age above 75. B. suspected dissecting aortic aneurysm. C. past cerebral stroke 2 years ago. D. high blood pressure >175/110 mmHg. E. invasive cardiology unit available on duty, which can be reached within 90 minutes.
    [Show full text]
  • Revisiting Hemochromatosis: Genetic Vs
    731 Review Article on Unresolved Basis Issues in Hepatology Page 1 of 16 Revisiting hemochromatosis: genetic vs. phenotypic manifestations Gregory J. Anderson1^, Edouard Bardou-Jacquet2 1Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute and School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia; 2Liver Disease Department, University of Rennes and French Reference Center for Hemochromatosis and Iron Metabolism Disease, Rennes, France Contributions: (I) Conception and design: Both authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Gregory J. Anderson. Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia. Email: [email protected]. Abstract: Iron overload disorders represent an important class of human diseases. Of the primary iron overload conditions, by far the most common and best studied is HFE-related hemochromatosis, which results from homozygosity for a mutation leading to the C282Y substitution in the HFE protein. This disease is characterized by reduced expression of the iron-regulatory hormone hepcidin, leading to increased dietary iron absorption and iron deposition in multiple tissues including the liver, pancreas, joints, heart and pituitary. The phenotype of HFE-related hemochromatosis is quite variable, with some individuals showing little or no evidence of increased body iron, yet others showing severe iron loading, tissue damage and clinical sequelae. The majority of genetically predisposed individuals show at least some evidence of iron loading (increased transferrin saturation and serum ferritin), but a minority show clinical symptoms and severe consequences are rare.
    [Show full text]
  • EASL Clinical Practice Guidelines: Wilson's Disease
    Clinical Practice Guidelines EASL Clinical Practice Guidelines: Wilson’s disease ⇑ European Association for the Study of the Liver Summary with acute liver failure. Wilson’s disease is not just a disease of children and young adults, but may present at any age [5]. This Clinical Practice Guideline (CPG) has been developed to Wilson’s disease is a genetic disorder that is found worldwide. assist physicians and other healthcare providers in the diagnosis Wilson’s disease is recognized to be more common than previ- and management of patients with Wilson’s disease. The goal is to ously thought, with a gene frequency of 1 in 90–150 and an inci- describe a number of generally accepted approaches for diagno- dence (based on adults presenting with neurologic symptoms sis, prevention, and treatment of Wilson’s disease. Recommenda- [6]) that may be as high as 1 in 30,000 [7]. More than 500 distinct tions are based on a systematic literature review in the Medline mutations have been described in the Wilson gene, from which (PubMed version), Embase (Dialog version), and the Cochrane 380 have a confirmed role in the pathogenesis of the disease [8]. Library databases using entries from 1966 to 2011. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system used in other EASL CPGs was used and set against the somewhat different grading system used in the Clinical presentation AASLD guidelines (Table 1A and B). Unfortunately, there is not a single randomized controlled trial conducted in Wilson’s dis- The most common presentations are with liver disease or neuro- ease which has an optimal design.
    [Show full text]
  • Electrolyte and Acid-Base Disorders Triggered by Aminoglycoside Or Colistin Therapy: a Systematic Review
    antibiotics Review Electrolyte and Acid-Base Disorders Triggered by Aminoglycoside or Colistin Therapy: A Systematic Review Martin Scoglio 1,* , Gabriel Bronz 1, Pietro O. Rinoldi 1,2, Pietro B. Faré 3,Céline Betti 1,2, Mario G. Bianchetti 1, Giacomo D. Simonetti 1,2, Viola Gennaro 1, Samuele Renzi 4, Sebastiano A. G. Lava 5 and Gregorio P. Milani 2,6,7 1 Faculty of Biomedicine, Università della Svizzera Italiana, 6900 Lugano, Switzerland; [email protected] (G.B.); [email protected] (P.O.R.); [email protected] (C.B.); [email protected] (M.G.B.); [email protected] (G.D.S.); [email protected] (V.G.) 2 Department of Pediatrics, Pediatric Institute of Southern Switzerland, Ospedale San Giovanni, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland; [email protected] 3 Department of Internal Medicine, Ospedale La Carità, Ente Ospedaliero Cantonale, 6600 Locarno, Switzerland; [email protected] 4 Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; [email protected] 5 Pediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] 6 Pediatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy 7 Department of Clinical Sciences and Community Health, Università degli Studi di Milano, 20122 Milan, Italy * Correspondence: [email protected] Citation: Scoglio, M.; Bronz, G.; Abstract: Aminoglycoside or colistin therapy may alter the renal tubular function without decreasing Rinoldi, P.O.; Faré, P.B.; Betti, C.; the glomerular filtration rate. This association has never been extensively investigated.
    [Show full text]
  • Diagnosis and Treatment of Wilson Disease: an Update
    AASLD PRACTICE GUIDELINES Diagnosis and Treatment of Wilson Disease: An Update Eve A. Roberts1 and Michael L. Schilsky2 This guideline has been approved by the American Asso- efit versus risk) and level (assessing strength or certainty) ciation for the Study of Liver Diseases (AASLD) and rep- of evidence to be assigned and reported with each recom- resents the position of the association. mendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Prac- Preamble tice Guidelines3,4). These recommendations provide a data-supported ap- proach to the diagnosis and treatment of patients with Introduction Wilson disease. They are based on the following: (1) for- Copper is an essential metal that is an important cofac- mal review and analysis of the recently-published world tor for many proteins. The average diet provides substan- literature on the topic including Medline search; (2) tial amounts of copper, typically 2-5 mg/day; the American College of Physicians Manual for Assessing recommended intake is 0.9 mg/day. Most dietary copper 1 Health Practices and Designing Practice Guidelines ; (3) ends up being excreted. Copper is absorbed by entero- guideline policies, including the AASLD Policy on the cytes mainly in the duodenum and proximal small intes- Development and Use of Practice Guidelines and the tine and transported in the portal circulation in American Gastroenterological Association Policy State- association with albumin and the amino acid histidine to 2 ment on Guidelines ; (4) the experience of the authors in the liver, where it is avidly removed from the circulation. the specified topic.
    [Show full text]
  • Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros Bicornis)
    animals Review Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis) Kathleen E. Sullivan, Natalie D. Mylniczenko , Steven E. Nelson Jr. , Brandy Coffin and Shana R. Lavin * Disney’s Animal Kingdom®, Animals, Science and Environment, Bay Lake, FL 32830, USA; [email protected] (K.E.S.); [email protected] (N.D.M.); [email protected] (S.E.N.J.); Brandy.Coffi[email protected] (B.C.) * Correspondence: [email protected]; Tel.: +1-407-938-1572 Received: 29 September 2020; Accepted: 26 October 2020; Published: 29 October 2020 Simple Summary: Black rhinoceros under human care are predisposed to Iron Overload Disorder that is unlike the hereditary condition seen in humans. We aim to address the black rhino caretaker community at multiple perspectives (keeper, curator, veterinarian, nutritionist, veterinary technician, and researcher) to describe approaches to Iron Overload Disorder in black rhinos and share learnings. This report includes sections on (1) background on how iron functions in comparative species and how Iron Overload Disorder appears to work in black rhinos, (2) practical recommendations for known diagnostics, (3) a brief review of current investigations on inflammatory and other potential biomarkers, (4) nutrition knowledge and advice as prevention, and (5) an overview of treatment options including information on chelation and details on performing large volume voluntary phlebotomy. The aim is to use evidence to support the successful management of this disorder to ensure optimal animal health, welfare, and longevity for a sustainable black rhinoceros population. Abstract: Critically endangered black rhinoceros (BR) under human care are predisposed to non-hemochromatosis Iron Overload Disorder (IOD).
    [Show full text]
  • Front Matter (PDF)
    HIGH RATE OF SUCCESS IN AN NIH-SPONSORED STUDY of hypertensive patients- the highest 83% withpercentageNORVASC#{174}- remained(amlodipineon initialbesylate)therapy after 4 years; nearly all patients were on the 5-mg starting dose’ LOW RATE OF DISCONTINUATION NY J50,oof(n=patients1730) discontinuedin placebo-controlledtherapy duestudiesto adverse effects2 PROVEN SAFETY No negative inotropic effects at clinical doses in hemodynamic studies2* No clinically significant effect on cardiac conduction or heart rate2 * Similar hemodynamic findings, however, have been observed with agents possessing significant negative inotropic effects. 5-mg and 10-mg tablets Once-Daily (amlodipinebesylate) EFFICACY AND SAFETY THAT’S EASY TO LIVE WITH Brief Summary NORVASC (amtodlpfne besylate) Tablets For Oral Use CONTRAINDICATIONS: NORVASC is conlraindicaled in palients wilh known sensitivity to amlodipine In hypertension WARNINGS: Increased Angina and/or Myocardlal Infarction: Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration and/sr severity of angina or acute myscardiat infarction on starting calcium channel blocker therapy or atthe time of dosage increase The mechanism of this effect has not been elucidated. PRECAUTIONS: General: Since the vasodilation induced by NORVASC is gradual in onset, acute hypvtension has rarely been reported after oral administration of NORVASC. Nonetheless, caution should be evercised when admin- or angina,convenient istering NORVASC as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. Use In Patients wIth CongestIve Heart FaIlure: In general, calcium channel blockers should be used with caution in patients with heart failure. NORVASC (5-10 mg per day) has been studied in a placebo-controlled trial of 1153 patients with NYHA Class Ill or IV heart failure vn stable doses of ACE inhibitor, digoxin.
    [Show full text]
  • Evaluating and Treating the Kidneys
    16_Nephrology.qxd 8/23/2005 10:41 AM Page 451 CHAPTER 16 Evaluating and Treating the Kidneys M. SCOTT ECHOLS, DVM, D ipl ABVP-A vian Renal diseases and their various classifications are well documented in the avian literature. The precise patho- genesis of avian renal disease, however, is not nearly as well described as it is in mammals. Renal disease has been shown to be fairly common in avian species. In studied poultry, as much as 29.6% of all disease condi- tions had abnormal pathology associated with or attrib- utable to renal disorders.20,214,251 Amyloidosis, urate nephrosis and gout were the most common diseases associated with mortality in a 4-year retrospective study conducted at a waterfowl park in Ontario, Canada.210 Thirty-seven percent of all avian cases presenting with renal tissue for histopathological examination, included over a 15-month period at the Schubot Exotic Bird Health Center, had one or more histologically identified kidney lesions.187 Nine of 75 pheasants (Phasianus colchicus) died with nephritis, one or both ureters impacted, and visceral gout in another comprehensive study on avian mortality.186 These case reports and retro- spective studies support the conclusion that renal dis- eases are relatively common and are clinically significant in multiple avian species. When compared to mammalian counterparts, the avian urogenital system has many structural and functional differences, which have been described previously.77,90,118,181,187,227 Differences including gross anatomy, renal portal blood flow and protein waste elimination should be considered when reviewing this chapter, as findings obtained from mammalian studies may not necessarily be applicable to birds.
    [Show full text]
  • Cardiac Impairment Due to Hypocalcemia in a Multitransfused Patient with Thalassemia Major S Ansari, a Kiumarsi, T Rostami
    The Internet Journal of Hematology ISPUB.COM Volume 10 Number 1 Cardiac Impairment Due To Hypocalcemia In A Multitransfused Patient With Thalassemia Major S Ansari, A Kiumarsi, T Rostami Citation S Ansari, A Kiumarsi, T Rostami. Cardiac Impairment Due To Hypocalcemia In A Multitransfused Patient With Thalassemia Major. The Internet Journal of Hematology. 2014 Volume 10 Number 1. Abstract We report a case of a 16-year-old Iranian girl with transfusion-dependent thalassemia major who presented with chest pain. Laboratory investigations showed marked hypocalcemia, hypomagnesaemia, hyperphosphatemia, and an extremely low vitamin D3 level. She had a low parathyroid hormone (PTH) level. She was refractory to calcium and magnesium supplementation. However, she responded to oral cacitriol. She was diagnosed to have hypoparathyroidism most likely due to iron overload due to multitransfusions and vitamin D3 deficiency. Vitamin D3 deficiency most likely was independent of iron overload. Cardiomyopathy in this patient could have been secondary to iron overload and/or hypocalcemia. Hypocalcemia could have been due to hypoparathyroidism and/or the low vitamin D3 level. Her response to calcitriol but not to calcium and magnesium supplementation suggests that the hypocalcemia was due to hypoparathyroidism and/or vitamin D3 deficiency. The response to calcitriol also indicates that iron overload was not responsible since cardiac impairment due to iron overload would be refractory to calcitriol treatment. Cardiac failure in multitransfused patients is usually ascribed to hemosiderosis. This case demonstrates that hypocalcemia related to vitamin D3 insufficiency also can cause myocardial dysfunction. Patients with thalassemia minor should be periodically screened for calcium and vitamin D3 levels to avoid complications secondary to hypocalcemia.
    [Show full text]
  • Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients with Uncomplicated Type 1 Diabetes
    Diabetes Volume 66, July 2017 1939 Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes Yuliya Lytvyn,1,2 Ronnie Har,1 Amy Locke,1 Vesta Lai,1 Derek Fong,1 Andrew Advani,3 Bruce A. Perkins,4 and David Z.I. Cherney1 Diabetes 2017;66:1939–1949 | https://doi.org/10.2337/db17-0168 Higher plasma uric acid (PUA) levels are associated with at the efferent arteriole. Ongoing outcome trials will de- lower glomerular filtration rate (GFR) and higher blood termine cardiorenal outcomes of PUA lowering in patients pressure (BP) in patients with type 1 diabetes (T1D). Our with T1D. aim was to determine the impact of PUA lowering on renal and vascular function in patients with uncomplicated T1D. T1D patients (n = 49) were studied under euglycemic and Plasma uric acid (PUA) levels are associated with the PATHOPHYSIOLOGY hyperglycemic conditions at baseline and after PUA low- pathogenesis of diabetic complications, including cardiovas- ering with febuxostat (FBX) for 8 weeks. Healthy control cular disease and kidney injury (1). Interestingly, extracellu- subjects were studied under normoglycemic conditions lar PUA levels are lower in young adults and adolescents (n = 24). PUA, GFR (inulin), effective renal plasma flow with type 1 diabetes (T1D) compared with healthy control (para-aminohippurate), BP, and hemodynamic responses subjects (HCs) (2–4), likely due to a stimulatory effect of to an infusion of angiotensin II (assessment of intrarenal urinary glucose on the proximal tubular GLUT9 transporter, renin-angiotensin-aldosterone system [RAAS]) were mea- which induces uricosuria (2). Thus, PUA-mediated target sured before and after FBX treatment.
    [Show full text]